About kidswell bio corp - GNTA
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.
GNTA At a Glance
Genenta Science SpA
Via Olgettina No. 58
Milan, Milan 20132
| Phone | 39-02-2643-4681 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -7,369,418.77 | |
| Sector | Health Technology | Employees | 9 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GNTA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.361 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.706 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 1.705 |
GNTA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -818,824.308 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GNTA Liquidity
| Current Ratio | 14.155 |
| Quick Ratio | 14.155 |
| Cash Ratio | 13.291 |
GNTA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -27.913 |
| Return on Equity | -38.193 |
| Return on Total Capital | -21.311 |
| Return on Invested Capital | -31.016 |
GNTA Capital Structure
| Total Debt to Total Equity | 34.811 |
| Total Debt to Total Capital | 25.822 |
| Total Debt to Total Assets | 23.842 |
| Long-Term Debt to Equity | 34.811 |
| Long-Term Debt to Total Capital | 25.822 |